Tumor bioimmunotherapy is an emerging tumor treatment mode with significant efficacy, and is a new type of autoimmune anti-cancer treatment method. It is a method of using biotechnology and biological agents to cultivate and expand immune cells collected from patients in vitro and then transfuse them back into patients’ bodies to stimulate and enhance the body’s own immune function, so as to achieve the purpose of treating tumors. Tumor biotherapy is the fourth major tumor treatment technology after surgery, radiotherapy and chemotherapy. Dendritic cells (DCs) are the most powerful and the only specialized antigen-presenting cells known to activate resting T cells in the body, and are central to the initiation, regulation and maintenance of the immune response. Activated dendritic cells have now become one of the effective therapeutic tools for the treatment of tumors and hold promise for the treatment of many other diseases including infectious diseases, autoimmune diseases and transplant rejection. Cytokine-induced killer (CIK) cells are a kind of immune effector cells with T-cell anti-tumor activity and NK-cell non-MHC-restricted tumor killing; they have the advantages of rapid proliferation, high tumor killing activity, broad tumor killing spectrum, and low toxic side effects, etc. CIK cells are a group of heterogeneous cells obtained by co-culturing human peripheral blood single nucleus cells with various cytokines in vitro, which have powerful It has the advantages of powerful anti-tumor activity and non-restrictive tumor killing, and can be used for patients with any stage of cancer. Specific autologous tumor-sustaining immunotherapy using DC and CIK cells has become a new hot topic in tumor research, and is a new modality alongside surgery, radiotherapy and chemotherapy, and is one of the most effective ways to stimulate the body’s immune system to fight against cancer. It is now becoming more and more accepted and considered as a true sense of immunotherapy. The treatment process of tumor bioimmunotherapy is divided into three main parts: peripheral blood collection – cell culture – transfusion back. That is, immature immune cells in peripheral blood are extracted from the patient’s body, cultured with in vitro cellular antigen load using the latest US patented technology, so that their tumor-killing activity increases several to tens of times, and then transfused back into the patient’s body. On the premise of not damaging and destroying the immune system and function of the body, it directly identifies, kills and destroys the cancer cells existing in the blood and lymph of human body, and restores and enhances the natural anti-cancer immune system and function of the body. Biological immunotherapy for malignant tumors has the following advantages: 1. For some cancers, the efficiency is as high as 70%. 2. No toxic side effects of radiotherapy and chemotherapy, no pain for patients, good tolerance and strong specificity for tumor killing. 3. It can stimulate the systemic anti-cancer effect and is equally effective for multiple foci or metastatic malignant tumors; 4. It can help the body to quickly recover the anti-cancer immune system destroyed by radiotherapy and chemotherapy and improve the long-term anti-cancer ability. 5.It is effective in preventing recurrence of cancer after surgery and has good long-term anti-cancer effect. 6.It can be used alone or in combination with other treatment methods. It is effective for single use and better for multiple use.